Anxiety

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and...

The scientific review comes as Americans are increasingly turning to the plant to cope with chronic pain, sleep difficulties, anxiety and a wide range of other health concerns.

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Vistagen Therapeutics, Inc. (“Vistagen”...

NEW YORK--(BUSINESS WIRE)--Jan 16, 2026--

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company presented new clinical and preclinical

Gaustad, 19, shares her mental health journey with Know Your Value. “It’s easier to struggle with someone else than to struggle alone,” she says.

(MENAFN - GlobeNewsWire - Nasdaq) 16-bed crisis triage center is the final program to launch in new state-of-the-art facility, following the December 2025 opening of the 16-bed Evaluation and ...

MELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, the Company's oral fixed-dose combination product candidate for the treatment of obstructive sleep a

Psilocybin—the psychedelic compound that occurs naturally in certain "magic" mushroom species—has been shown in trials to provide long-term treatment for depression and anxiety. But the chemical's hallucinogenic effects can make developing treatments expensive and pose significant risks to people living with other psychiatric illnesses.

-- Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 -- -- Enrolling Phase 2 REKINDLE Trial of RE104 in Adjustment Disorder (AjD); Initial Data Expected in 1Q 2027 ---- On Track to Initiate Phase 2 RECLAIM Trial in Generalized Anxiety Disorder (GAD) in 1Q 2026 -- MORRISTOWN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company co

LSD became notorious during the drug culture of the 1960s as a powerful hallucinogen. But a form of that drug shows promise for treating anxiety and is now being tested in Charleston and elsewhere.

There is a link between mental health and heart health. That means treating anxiety, depression, or PTSD may help prolong your life.